)
Neumora Therapeutics (NMRA) investor relations material
Neumora Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Clinical-stage pipeline includes NMRA-511 for agitation associated with Alzheimer’s dementia, NMRA-898 for schizophrenia and NMRA-215 for obesity and cardiometabolic disease; no product sales revenue to date.
Navacaprant development for MDD was discontinued after KOASTAL-2 and -3 missed primary and key secondary endpoints; a ~35% workforce reduction followed in June 2026.
NMRA-215 IND was submitted to the FDA; additional NMRA-511 dose-escalation data were reported.
Financial highlights
Q3 2026 net loss was $34.4M, or $0.18/share, versus $56.8M, or $0.35/share, in Q3 2025; 9M net loss was $131.0M versus $177.5M.
Q3 operating expenses were $33.4M versus $57.7M; 9M operating expenses were $128.5M versus $182.7M, including $5.0M of acquired in-process R&D in each 2025 nine-month period.
Q3 R&D expense was $22.6M versus $40.5M, and G&A expense was $10.8M versus $12.2M; lower clinical trial and personnel costs drove the declines.
Cash and cash equivalents were $85.7M at September 30, 2026; accumulated deficit reached $1,315.1M.
9M operating cash use was $119.4M versus $158.5M; financing provided $22.5M, mainly from ATM stock sales.
Outlook and guidance
Available cash is not expected to fund operating plans for at least 12 months from issuance of the financial statements; substantial doubt about continuing as a going concern was concluded.
Significant losses and negative operating cash flows are expected to continue as clinical and preclinical programs advance; product revenue is not expected for years, if ever.
Additional funding is required to continue operations and develop product candidates; expected sources include equity or debt financing, collaborations or other capital, with no assurance of availability or acceptable terms.
Management cited disciplined capital allocation toward programs with the greatest potential value and evaluation of financing options to fund lead programs through upcoming value inflection points.
- Advancing brain-penetrant therapies with strong early results for major CNS and metabolic diseases.NMRA
Company presentation - Net loss narrowed, cash runway extends into Q3 2027, but going concern risk persists.NMRA
Q2 2026 - Advancing differentiated CNS therapies with strong efficacy and safety toward late-2026 milestones.NMRA
Corporate presentation - Navacaprant's phase III COASTAL Program targets MDD and anhedonia, with pivotal data expected Q4.NMRA
Status Update - Lead programs show strong efficacy and safety, with key clinical milestones expected in 2026.NMRA
Investor presentation - Directors re-elected, auditor ratified, and annual executive pay votes approved.NMRA
AGM 2026 - Navacaprant, NMRA-511, NMRA-215, and NMRA-898 advance with key data readouts and clinical milestones ahead.NMRA
RBC Capital Markets Global Healthcare Conference 2026 - NMRA-215 showed up to 26% preclinical weight loss; multiple clinical catalysts expected in 2026.NMRA
R&D Day 2025 - Pivotal Phase 3 MDD data expected year-end, with $341.3M cash runway into mid-2026.NMRA
Q3 2024
)
)
)
)
)
)
)
)